Search results :

Imiquimod

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: D06BB10

Side effects

Options: Show MedDRA Preferred Terms,   display only 20 labels

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Application site reaction common, 2.79% - 33% x x x x x x x x x x x x x x x x x x
Pruritus uncommon, 0.4% - 32.5% x x x x x x x x x x x x x x x x x x x x x x
Erythema uncommon, 0% - 100% x x x x x x x x x x x x x x x x x x x x x x x
Upper respiratory tract infection uncommon, 0.1% - 15.3% x x x x x x x x x x x x x x x x
Excoriation 0% - 26% x x x x x x x x x x x x x x x x x x x x
Sinusitis 1% - 7.44% x x x x x x x x x x x x x x x x x
Application site erythema common x x
Application site burn common x x x x x x x x x x
Application site pruritus very common, 0.629% - 4.38% x x x x
Headache common, 0.4% - 8% x x x x x x x x x x x x x x x x x x x x x x x
Application site irritation common, 0% - 6% x x x x
Application site pain common — 0% - 7% x x x x
Scab 0% - 83% x x x x x x x x x x x x x x x x x x x x x x x
Squamous cell carcinoma 2.26% - 3.72% x x x x x x x x x x x x x x x x x
Application site rash uncommon, common x x x x
Application site haemorrhage uncommon, common x x x x
Application site paraesthesia uncommon, common x x
Application site papules uncommon, common x x
Fungal infection uncommon, 0.1% - 11.1% x x x x x x x x x x x x x x x x x x x
Ulcer 0% - 48% x x x x x x x x x x x x x x x x x x x x x
Induration 0% - 84% x x x x x x x x x x x x x x x x x x x
Pain uncommon, 0% - 8% x x x x x x x x x x x x x x x x x x x x x
Hypertension 1.4% x x x
Fatigue common, 0% - 4.38% x x x x x x x x x x x x x x x x x x x x x x x
Dyspepsia 1% - 2% x x x x x x x x
Bone pain 1.12% - 1.62% x x x
Eczema uncommon, 0.1% - 1.86% x x x x x x x x x x x x x x x x x x
Influenza-like symptoms 0% - 3.42% x x x x x x x x x x x x x x x x x x x x x x
Vaginitis bacterial 0.99% - 1.5% x x
Viral infection 0.905% - 1.4% x x x x x x x x x x x x x x x
Back pain uncommon — 0.2% - 4% x x x x x x x x x x x x x x x x x x x x x
Stinging 0.905% - 2.79% x x x x x x x x x x x x x x x x x x x
Cough 1% - 2% x x x x x x x x
Nausea uncommon — 0% - 3.75% x x x x x x x x x x x x x x
Tenderness 0% - 4% x x x x x x x x x x x x x x x x x x x
Lymphadenopathy uncommon — 0% - 3% x x x x x x x x x x x x x
Anxiety 1% - 1.1% x x x x x x x
Oedema 0% - 78% x x x x x x x x x x x x x x x x x x x x x x
Papule 0% - 1.62% x x x x x x x x
Urinary tract infection 0.452% - 1.4% x x x x x x x x x x x x x x x
Atrial fibrillation postmarketing, 0.905% - 1.4% x x x x x x x x x x x x x x x x x x
Diarrhoea uncommon, 0% - 2.79% x x x x x x x x x x x x x x x x x x x x x x x
Myalgia common, 0% - 2% x x x x x x x x x x x x x x x x x x x x x x x
Pustule uncommon — 0.4% - 1.1% x x x x
Allergy aggravated 0.559% - 1.08% x x
Body temperature increased uncommon, 0% - 3.12% x x x x x x x x x x x x x x x x x x x x x x x
Hyperaesthesia 0.8% x
Haemorrhage 0% - 3.26% x x x x x x x x x x x x x x x x x x x
Alopecia 0% - 1.4% x x x x x x x x x x x x x x x x x x x
Discomfort uncommon, 0.8% x x x x
Rigors uncommon, 0% - 1.4% x x x x x x x x x x x x x x x x x x
Dizziness uncommon, 0% - 2.5% x x x x x x x x x x x x x x x x x x x x x
Tooth disorder 0% - 1.12% x x
Pharyngitis uncommon, 0.1% - 1.08% x x x x x x x x x x x
Asthenia uncommon, 0.2% - 0.8% x x x x
Depression uncommon, 0.1% - 0.8% x x x x
Rash uncommon, 0.1% - 1.1% x x x x x x x x x x x x x x x x x x x x x x
Flushing uncommon, 0.1% - 0.8% x x x
Paraesthesia uncommon, 0.4% - 1.7% x x x
Rhinitis uncommon, 0.1% - 3% x x x x x x x x x x x
Application site oedema uncommon x x
Application site ulcer uncommon x x
Influenza like illness uncommon, 0% - 3.75% x x x x x x
Application site warmth uncommon x x
Application site vesicles uncommon x x
Application site inflammation uncommon x x
Application site hyperaesthesia uncommon x x
Application site discharge uncommon x x
Application site scab uncommon x x
Application site skin breakdown uncommon x x
Application site swelling uncommon x x x x
Application site scar uncommon x x
Gout 0% - 1.08% x x
Malnutrition 0% - 1.08% x x x x x x
Irritability uncommon, 0.5% x x x x
Lethargy uncommon, 0.5% x x x x x x
Dry mouth uncommon, 0.5% x x x x
Vomiting uncommon, 0.2% - 1.4% x x x x x x x x x x x x x x x x x x x x x
Dermatitis uncommon, 0.2% - 0.5% x x x x x x x x x
Inflammation uncommon, 0.4% - 0.5% x x x x
Skin breakdown 0.5% x x x x
Tearfulness 0% - 22% x x x x x x x x x x x x x x x x x
Influenza uncommon, 0.4% x x x
Actinic keratosis uncommon, 0.4% x x
Nasal congestion uncommon, 0.4% x x x x
Pain in extremity uncommon, 0.4% x x x x
Skin ulcer uncommon, 0.4% x x x x
Eyelid oedema uncommon, 0.4% x x x x
Conjunctival irritation uncommon, 0.4% x x x x
Face oedema uncommon, 0.4% x x x x
Pharyngolaryngeal pain uncommon, 0.4% x x x x
Swelling 0.4% - 0.5% x x
Urticaria uncommon, 0.1% - 0.4% x x x
Warmth 0.4% x x
Scar 0.4% x x
Anorexia uncommon — 0% - 2.5% x x x x x x
Penis disorder uncommon, 0.2% x x x
Vaginal inflammation uncommon, 0.2% x x x
Malaise uncommon, 0.2% x x x
Genital candidiasis uncommon, 0.2% x x x
Genital pain male uncommon, 0.2% x x x
Bacterial infection uncommon, 0.1% x x
Folliculitis uncommon, 0.1% x x x
Rectal disorder uncommon, 0.1% x x x
Tinnitus uncommon, 0.1% x x x
Vulval disorder uncommon, 0.1% x x x
Vulvitis uncommon, 0.1% x x x
Migraine uncommon, 0.1% x x x
Uterovaginal prolapse uncommon, 0.1% x x
Vaginitis atrophic uncommon, 0.1% x x x
Rectal tenesmus uncommon, 0.1% x x
Rash erythematous uncommon, 0.1% x x x
Vaginal pain uncommon, 0.1% x x x
Erectile dysfunction uncommon, 0.1% x x x
Sweating increased uncommon, 0.1% x x x
Dyspareunia uncommon, 0.1% x x x
Somnolence uncommon, 0.1% x x x
Abdominal pain postmarketing — 0.3% - 1.12% x x x x x x x x x x x x x x x x
Angioedema postmarketing x x x x x x x x x x x x x x x x
Arrhythmia postmarketing x x x x x x x x x x x x x x x x
Arthralgia postmarketing — 0% - 2.5% x x x x x x x x x x x x x x x x x x
Chest pain postmarketing, 0% - 1.08% x x x x x x x x x x x x x x x x x x x
Infection postmarketing — 0% - 1.4% x x x x x x x x x x x x x x x x x x x x x x
Febrile convulsion postmarketing x x x x x x x x x x x x x x x
Dermatitis exfoliative postmarketing x x x x x x x x x x x x x x x x
Dyspnoea postmarketing x x x x x x x x x x x x x x x x
Dysuria postmarketing — 0.4% x x x x x x x x x x x x x x
Erythema multiforme postmarketing x x x x x x x x x x x x x x x x x x x
Cardiac failure postmarketing x x x x x x x x x x x x x x x x
Herpes simplex postmarketing — 0% - 2.5% x x x x x x x x x x x x x x x x x x
Ischaemia postmarketing x x x x x x x x x x x x x x x x
Lymphoma postmarketing x x x x x x x x x x x x x
Multiple sclerosis postmarketing x x x x x x x x x x x x x x x x
Myocardial infarction postmarketing x x x x x x x x x x x x x x x x
Palpitations postmarketing x x x x x x x x x x x x x x x x
Paresis postmarketing x x x x x x x x x x x x x x x x
Proteinuria postmarketing x x x x x x x x x x x x x x x x
Pulmonary oedema postmarketing x x x x x x x x x x x x x x x x
Henoch-Schonlein purpura postmarketing x x x x x x x x x x x x x x x
Convulsion postmarketing x x x x x x x x x x x x x x x x
Cerebrovascular accident postmarketing x x x x x x x x x x x x x x x x
Suicide postmarketing x x x x x x x x x x x x x x x x
Syncope postmarketing x x x x x x x x x x x x x x x x
Tachycardia postmarketing x x x x x x x x x x x x x x x x
Supraventricular tachycardia postmarketing x x
Thyroiditis postmarketing x x x x x x x x x x x x x x x x
Urinary tract disorder postmarketing x x x x x x x x x x x x x x x x x x x x
Idiopathic thrombocytopenic purpura postmarketing x x x x x x x x x x x x x x x
Urinary retention postmarketing x x x x x x x x x x x
Agitation postmarketing x x x x x x x x x x x x x x x x
Hepatic function abnormal postmarketing x x x x x x x x x x x x x x x x
Hypertrophic scar postmarketing x x x x x x x x x x x
Skin hyperpigmentation postmarketing x x x x x x x x x x x x x x x x x x x
Leukoderma postmarketing, 1.1% x x x x x x x x x x x x x x x x x x x x x x x
Capillary leak syndrome postmarketing x x x x x x x x x x x x x x x x
Infestation NOS postmarketing x x x x x x x x x x x x x x
Cardiomyopathy postmarketing x x x x x x x x x x x x x x x x
Insomnia postmarketing — 0.2% - 0.4% x x x x x x x x x x x x x x x x x x x x
Hepatic lymphoma postmarketing x x
Tingling sensation postmarketing x x x x x x x x x x x x
Arthritis x x x
Mental disorder x x x x x x
Breast disorder x x x
Bronchitis x x x
Basal cell carcinoma x
Cardiovascular disorder x x x
Cheilitis 0% - 1.88% x x
Conjunctivitis x x x x
Connective tissue disorder x x x x
Cyst x x x
Congenital eye disorder x x x
Eye disorder x x x x
Eye infection x x x
Gastrooesophageal reflux disease x
Gastrointestinal disorder x x x x x
Hernia x x x
Herpes zoster x x
Hypercholesterolaemia x x x
Immune system disorder x
Cutaneous lupus erythematosus x x x x
Mediastinal disorder x x x x
Nervous system disorder x x x x x x x
Otitis media x
Postoperative pain x x x
Pancytopenia x x
Neuropathy peripheral x x x x x x x x x x x x x x x x x
Pregnancy x x
Psoriasis x x
Skin disorder x x x
Skin infection x x x x
Stevens-Johnson syndrome x x x x
Angiopathy x x x
Disorder sight x x x
Common wart x x x
Chills x x x
Scrotal oedema x x
Haemoglobin decreased x
Photosensitivity reaction x x x
Unspecified disorder of skin and subcutaneous tissue x x x
Immobile x
Teratogenicity x
Psoriasis flare-up x x
Hepatic enzyme increased x x
Scrotal pain x x
Skin exfoliation x
Low set ears x
Scrotal erythema x x
Pulmonary congestion x x x
Exencephaly x
Hepatobiliary disease x
Scrotal ulcer x x
Oral herpes 0% - 2.5% x x
Platelet count decreased x
Skin oedema x
Pre-existing disease x x
Inflicted injury x x x
Procedural site reaction x x
Blood glucose increased x
White blood cell count decreased x x
Blood and lymphatic system disorders x x x
Ear and labyrinth disorders x x
Neutrophil count decreased x
Local reaction x x x x x x x x x x x x x x x x
Hyperkeratosis x x x
Application site dryness x
Application site excoriation x x
Absolute neutrophil count decreased x
Abrasion NOS x x x
Tinea cruris x x x x x x x x x x x x x x x x x
Phototoxicity x x x x x
Application site exfoliation x
Application site cellulitis x x
Warts x x x x x x x x x x x x x x x x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

imiquimod / Aldara

Side effects:1
Source:FDA

imiquimod / Aldara

Side effects:23
Source:FDA

imiquimod

Side effects:84
Source:FDA Structured Product Label

imiquimod

Side effects:84
Source:FDA Structured Product Label

IMIQUIMOD

Side effects:64
Source:FDA Structured Product Label

IMIQUIMOD

Side effects:70
Source:FDA Structured Product Label

IMIQUIMOD

Side effects:78
Source:FDA Structured Product Label

IMIQUIMOD

Side effects:78
Source:FDA Structured Product Label

Imiquimod

Side effects:78
Source:FDA Structured Product Label

IMIQUIMOD

Side effects:78
Source:FDA Structured Product Label

IMIQUIMOD

Side effects:78
Source:FDA Structured Product Label

Imiquimod

Side effects:78
Source:FDA Structured Product Label

imiquimod

Side effects:87
Source:FDA Structured Product Label

Imiquimod

Side effects:87
Source:FDA Structured Product Label

Imiquimod

Side effects:79
Source:FDA Structured Product Label

imiquimod

Side effects:79
Source:FDA Structured Product Label

IMIQUIMOD / ALDARA

Side effects:87
Source:FDA

imiquimod / Aldara

Side effects:71
Source:FDA

IMIQUIMOD / ALDARA

Side effects:82
Source:FDA

IMIQUIMOD / ALDARA

Side effects:106
Source:FDA

imiquimod / imiquimod

Side effects:89
Source:EMA

Imiquimod / IMIQUIMOD CREAM

Side effects:103
Source:medicines.org.au

Imiquimod / ALDARATM

Side effects:112
Source:medicines.org.au

imiquimod / imiquimod

Side effects:119
Source:EMA

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label